Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Calidi Biotherapeutics will meet investors and share a virtual presentation at the September 2026 H.C. Wainwright investment conference.
Rhea-AI Summary
Calidi Biotherapeutics (CLDI) plans to participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14–16, 2026, at the Lotte New York Palace Hotel in New York.
Chief Executive Officer Eric Poma, Ph.D., will conduct one-on-one investor meetings during the conference dates. A virtual presentation will be available on-demand starting Friday, September 11, 2026, at 7:00 AM ET for registered attendees via the conference platform. Meeting requests and conference registration are available through the event website.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.
Eric Poma, Ph.D., Chief Executive Officer of Calidi Biotherapeutics will hold one-on-one meetings with investors from September 14 – 16. A virtual presentation will be available on-demand starting Friday, September 11 at 7:00 AM ET. The presentation will be available for registered attendees via the conference platform.
To request a meeting and to register for the conference: https://hcwevents.com/annualconference/
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.
CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.
Investors Contact:
IR@calidibio.com
Media Contact:
PR@calidibio.com
FAQ
How can investors access Calidi Biotherapeutics’ presentation and request a meeting?
The virtual presentation will be available on-demand for registered attendees via the conference platform starting Friday, September 11, 2026, at 7:00 AM ET. To request a one-on-one meeting with Calidi Biotherapeutics and to register for the H.C. Wainwright 28th Annual Global Investment Conference, interested parties are directed to visit https://hcwevents.com/annualconference/.